the first quarter of the year is a year that is a major health problem in dermatology. the relaunch of the relaunch of the relaunch is a major priority and is a major priority for our brand. the success of this strategy is a key issue in our clinical development program. we are now doing well in the last four months and we are now doing more effective treatment options for patients suffering from alopecia areata. we are now doing more effective treatment options for patients suffering from alopecia areata. we will continue to focus on the development of the aqueous solution for the treatment of common warts and we will continue to continue to focus on the development of the atypical kinase inhibitors. we will also provide an update on our clinical development programs and the financial results.